Clarivate has completed the $600 million sale of its Life Sciences & Healthcare segment to Altaris, advancing a broader effort to simplify the company’s portfolio and strengthen its balance sheet.
The transaction was originally announced on July 6, 2026.
Following the divestiture, Clarivate is concentrating its business around two primary segments: Academia & Government and Intellectual Property.
The company is positioning itself as a more focused, subscription-first provider of proprietary data, content, AI-powered intelligence, workflow software and technology-enabled services.
Its Academia & Government segment provides intelligence and workflow products to universities, research institutions, libraries, governments and funding organizations.
Products within the segment include Web of Science, ProQuest, Alma and Vega.
Clarivate’s Intellectual Property business provides patent, trademark, brand protection and innovation intelligence products, including IPOne, Derwent, CompuMark and IPfolio.
The company said both businesses are supported by proprietary content, workflow software and an expanding set of AI capabilities.
Clarivate intends to use proceeds from the $600 million transaction to reduce debt and strengthen its balance sheet, while increasing strategic and financial flexibility.
The company also expects the divestiture to support efforts to improve revenue quality, expand profitability and concentrate resources on long-term growth.
Clarivate plans to report third-quarter 2026 results on November 3 and update its full-year guidance to reflect the divestiture.
KEY QUOTES:
“This is an important milestone in Clarivate’s transformation journey. The successful completion of this transaction further advances our Value Creation Plan by sharpening our focus, simplifying our portfolio, and strengthening our financial profile. We are now positioned as a more focused company centered on two market-leading segments with attractive recurring revenue characteristics, deep customer relationships, and significant opportunities to leverage AI-driven innovation.
I want to thank our Life Sciences & Healthcare colleagues for their many contributions to Clarivate and wish them continued success as part of Altaris. We also thank our customers for their continued trust and partnership throughout this process.”
Matti Shem Tov, CEO of Clarivate
“The completion of this transaction marks another meaningful step in executing our strategy. Our streamlined business model and stronger balance sheet position us well to invest in innovation, support our customers, and drive sustainable growth and shareholder value.”
Michael Easton, Chief Financial Officer of Clarivate
